Skip to main content
NEXALIS THERAPEUTICS LTD logo

NEXALIS THERAPEUTICS LTD — Investor Relations & Filings

Ticker · NX1 ISIN · AU0000456733 ASX Professional, scientific and technical activities
Open in API
Filings indexed 509 across all filing types
Latest filing 2026-04-19 Regulatory Filings
Country AU Australia
Listing ASX NX1

About NEXALIS THERAPEUTICS LTD

https://nexalistherapeutics.com/

Nexalis Therapeutics Ltd focuses on the discovery and development of innovative small molecule therapies for the treatment of chronic inflammatory and autoimmune diseases. The company utilizes a proprietary drug discovery platform to target specific biological pathways, including the NLRP3 inflammasome, which is implicated in the progression of various systemic and neurodegenerative conditions. By developing highly selective and potent modulators, the organization aims to address significant unmet medical needs in patient populations suffering from debilitating inflammatory disorders. Research and development efforts are centered on translating complex biological insights into clinical-stage therapeutic candidates designed to improve patient outcomes and quality of life through precision targeting of immune system dysregulation.

Recent filings

Filing Released Lang Actions
Significant Milestone - First Patient Screened IRX-211 Ph2 3 pages 189.1KB
Regulatory Filings Classification · 80% confidence The document is a corporate press release announcing the clinical milestone of first patient screening in a Phase 2 trial of IRX-211. It does not present financial results (Earnings Release), regulatory form data, management changes, share transactions, or dividends. It is not an investor presentation or formal report itself, but a general update on business progress. Therefore it falls into the fallback category of general regulatory announcement or miscellaneous filing: Regulatory Filings (RNS).
2026-04-19 English
Phase 1 IRX-616a Trial Advances - Positive Safety Review 2 pages 141.2KB
Regulatory Filings Classification · 72% confidence The document is an ASX press release providing an operational update on the Phase 1 clinical trial of IRX-616a. It contains no financial results, fundraising, dividend, governance changes, or call transcript content. It does not fit any specific financial filing definition (e.g., Annual/Interim Report, Earnings Release, M&A, Capital Update). As a general company announcement, it falls under the fallback category for miscellaneous regulatory filings.
2026-04-16 English
2025 Corporate Governance Statement and 4G 32 pages 745.4KB
Governance Information Classification · 95% confidence The document is titled 'CORPORATE GOVERNANCE STATEMENT' and extensively discusses the company's governance framework, board responsibilities, management roles, board committees, policies, diversity and inclusion, risk management, and compliance with ASX Corporate Governance Council Principles and Recommendations. It includes references to board charters, nomination and remuneration policies, and other governance-related disclosures. There is no indication of financial statements, audit reports, earnings data, or other financial performance details. The content is focused on governance practices and policies rather than financial results or regulatory filings. Therefore, this document fits the category of Governance Information (CGR). The document length (15,000 characters) and detailed governance content support this classification with high confidence.
2026-03-30 English
2025 Annual Report 48 pages 2.4MB
Annual Report Classification · 100% confidence The document is titled 'Annual Report - 31 December 2025' and contains detailed sections typical of an annual report, including a Chairman's letter, Directors' report, financial results, business model, principal activities, and significant events during and after the financial year. It includes comprehensive information about the company's operations, financial performance, clinical trials, capital raising, and future outlook. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. There is no indication that this is merely an announcement of a report or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2025
2026-03-30 English
Nexalis to present at the NWR Virtual Healthcare Conference 1
Investor Presentation Classification · 90% confidence The document is a short announcement about Nexalis Therapeutics Ltd presenting at a virtual healthcare conference. It includes details about the presentation date, registration link, and contact information. There is no financial data, no detailed report, no regulatory filing, or any mention of financial results or corporate governance changes. The document is clearly an announcement of an investor presentation event rather than the presentation itself or a financial report. Given the content and length (2414 characters), it fits best as an Investor Presentation announcement. However, since it is only an announcement of the presentation event and not the presentation materials themselves, it aligns with the Investor Presentation (IP) category as per the definitions, which includes detailed presentations for investors focusing on financials, strategy, and market position. The document is not a report publication announcement (RPA) because it does not mention a report being published or attached, but rather an upcoming presentation event. Therefore, the best classification is Investor Presentation (IP).
2026-03-24 English
First patient dosed in IRX-616a Phase 1 trial 2 pages 99.2KB
Regulatory Filings Classification · 95% confidence The document is a company announcement about the commencement of dosing in a Phase 1 clinical trial for a drug candidate (IRX-616a). It provides highlights of the trial progress, safety review plans, and future study intentions. There are no financial statements, regulatory filings, or detailed financial data. The content is focused on clinical trial progress and company updates rather than financial results or regulatory compliance. The document length is 4243 characters, which is relatively short and reads like a press release or update rather than a formal report. This fits best under a general regulatory announcement or company update category rather than a financial or governance report. Therefore, the most appropriate classification is Regulatory Filings (RNS), which is the fallback for miscellaneous company announcements that do not fit other categories.
2026-03-18 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.